RxSight, Inc.
NASDAQ:RXSTMedical - Devices
+$0.05 today
- Market cap
- $210.07M
- Beta
- 1.13
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$1.13
Volume 0.74M
Average 0.80M
RXST Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
RxSight, Inc.NASDAQ: RXST
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $9.47M fell 8.6% year over year, behind the +2.6% change in trailing-twelve-month research & development. Sequentially, it rose 6.4% from the prior quarter. Over 3 fiscal years it compounded at +14.1% a year.
Context
- Research & development amounted to 28.7% of revenue in FY2025, up 4.1 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -8.6% toward the trailing-twelve-month pace of +2.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 38.55M USD
- Year-over-year change
- +12.2%
- 4-year CAGR
- +12.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.55M | +12.2% |
| FY2024 | 2024-12-31 | 34.37M | +18.3% |
| FY2023 | 2023-12-31 | 29.05M | +11.8% |
| FY2022 | 2022-12-31 | 25.98M | +6.0% |
| FY2021 | 2021-12-31 | 24.5M | — |
Research & Development vs competitors
How RXST compares with its peers on the latest reported figures
- RXST's LTM Mar 2026 research & development of $37.65M is the 2nd highest of the 9 companies compared; the peer median is $27.29M.
- Its year-over-year change of +2.6% is the 6th highest of 9, against a peer median of +8.4%.
- Research & development amounts to 29.5% of revenue for RXST, versus a peer median of 27.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $65.65M | +7.6% | +0.8% | 29.5% | |
| LTM Mar 2026 | $37.65M | +2.6% | +14.1% | 29.5% | |
| LTM Mar 2026 | $35.88M | -3.0% | -25.6% | 34.9% | |
| LTM Mar 2026 | $34.06M | +124.4% | +16.3% | 37.7% | |
| LTM Mar 2026 | $27.64M | +9.2% | +8.3% | 27.8% | |
| LTM Mar 2026 | $26.95M | +28.1% | +46.4% | — | |
| LTM Mar 2026 | $19.34M | -7.4% | +14.3% | 9.3% | |
| LTM Mar 2026 | $9.52M | +12.9% | +6.2% | 2.8% | |
| LTM Mar 2026 | $8.98M | -13.5% | +2.5% | 3.7% | |
| Peer median (excluding RXST) | $27.29M | +8.4% | +7.2% | 27.8% | |
Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 22.59M | 49.01M | 89.08M | 139.93M | 134.48M |
| Cost of Revenue | 18.08M | 27.68M | 35.31M | 40.98M | 31.47M |
| Gross Profit | 4.52M | 21.33M | 53.77M | 98.94M | 103.01M |
| Gross Margin | 20.0% | 43.5% | 60.4% | 70.7% | 76.6% |
| Research & Development | 24.5M | 25.98M | 29.05M | 34.37M | 38.55M |
| Selling, General & Admin | 32.81M | 58.67M | 74.8M | 101.43M | 112.65M |
| Operating Expenses | 57.3M | 84.65M | 103.85M | 135.8M | 151.2M |
| Depreciation & Amortization | 3.99M | 4.02M | 4.24M | 3.62M | 0 |
| EBITDA | (41.01M) | (57.78M) | (41.04M) | (23.76M) | (38.84M) |
| EBITDA Margin | -181.5% | -117.9% | -46.1% | -17.0% | -28.9% |
| Operating Income | (52.79M) | (63.32M) | (50.09M) | (36.86M) | (48.19M) |
| Operating Margin | -233.6% | -129.2% | -56.2% | -26.3% | -35.8% |
| Interest Income | 54K | 1.52M | 6.57M | 9.47M | 2.51M |
| Interest Expense | 3.68M | 4.95M | 3.31M | 21K | 40K |
| Other Income / Expenses | 4.11M | (3.43M) | 1.5M | 9.45M | 9.31M |
| Income Before Tax | (48.68M) | (66.75M) | (48.59M) | (27.41M) | (38.88M) |
| Pre-Tax Margin | -215.5% | -136.2% | -54.5% | -19.6% | -28.9% |
| Income Tax Expense | 8K | 9K | 20K | 50K | 66K |
| Net Income | (48.69M) | (66.76M) | (48.61M) | (27.46M) | (38.94M) |
| Net Margin | -215.5% | -136.2% | -54.6% | -19.6% | -29.0% |
| EPS (Basic) | (1.78) | (2.41) | (1.41) | (0.71) | (0.95) |
| EPS (Diluted) | (1.78) | (2.41) | (1.41) | (0.71) | (0.95) |
| Weighted Avg Shares | 27.37M | 27.66M | 34.46M | 38.87M | 41.18M |
| Weighted Avg Shares (Diluted) | 27.37M | 27.66M | 34.46M | 38.87M | 41.18M |
RxSight, Inc.
NASDAQ:RXST
Intrinsic Alpha fair value
Locked
Current Price
$5.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.